Prix Spectral Medical Inc (EDTXF)

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 29 full-time employees. The firm develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The firm also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. The company provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.